[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20020090L - Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler - Google Patents

Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler

Info

Publication number
NO20020090L
NO20020090L NO20020090A NO20020090A NO20020090L NO 20020090 L NO20020090 L NO 20020090L NO 20020090 A NO20020090 A NO 20020090A NO 20020090 A NO20020090 A NO 20020090A NO 20020090 L NO20020090 L NO 20020090L
Authority
NO
Norway
Prior art keywords
homocysteine
pharmaceutical
fatty acids
formulations containing
essential fatty
Prior art date
Application number
NO20020090A
Other languages
English (en)
Other versions
NO20020090D0 (no
Inventor
David Frederick Horrobin
Christina Gouaille
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of NO20020090D0 publication Critical patent/NO20020090D0/no
Publication of NO20020090L publication Critical patent/NO20020090L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
NO20020090A 1999-07-14 2002-01-08 Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler NO20020090L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9916536.7A GB9916536D0 (en) 1999-07-14 1999-07-14 Nutritional or pharmaceutical compositions
PCT/GB2000/002681 WO2001003696A1 (en) 1999-07-14 2000-07-11 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents

Publications (2)

Publication Number Publication Date
NO20020090D0 NO20020090D0 (no) 2002-01-08
NO20020090L true NO20020090L (no) 2002-01-08

Family

ID=10857244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020090A NO20020090L (no) 1999-07-14 2002-01-08 Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler

Country Status (24)

Country Link
US (1) US20050147665A1 (no)
EP (1) EP1200085A1 (no)
JP (1) JP2003504333A (no)
KR (1) KR20020025088A (no)
CN (1) CN1223346C (no)
AU (1) AU6167800A (no)
BR (1) BR0013157A (no)
CA (1) CA2377502A1 (no)
CZ (1) CZ200258A3 (no)
EE (1) EE200200021A (no)
GB (1) GB9916536D0 (no)
HK (1) HK1042853A1 (no)
HU (1) HUP0202342A3 (no)
IL (1) IL147556A0 (no)
IS (1) IS6205A (no)
MX (1) MXPA01013210A (no)
NO (1) NO20020090L (no)
NZ (1) NZ516101A (no)
PL (1) PL352185A1 (no)
RU (1) RU2001134300A (no)
SK (1) SK332002A3 (no)
TR (1) TR200200045T2 (no)
WO (1) WO2001003696A1 (no)
ZA (1) ZA200200259B (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
KR20020069539A (ko) * 2001-02-26 2002-09-05 주식회사 두산 뇌세포 보호용 조성물
KR100427637B1 (ko) * 2001-06-05 2004-04-27 이인규 세포내 에너지 소비 증가제
US20040176451A1 (en) * 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP1640011A1 (en) * 2002-06-20 2006-03-29 Astion Dermatology A/S Novel complexes of fatty acid esters of polyhydroxylalkanes and pyridine carboxy derivates
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
CA2492781A1 (en) * 2002-07-11 2004-01-22 Sankyo Company Limited Medicinal composition for mitigating blood lipid or lowering blood homocystein
US20040132819A1 (en) * 2002-08-06 2004-07-08 Nancy Auestad Appetite control method
AU2003270909A1 (en) * 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
KR20040063616A (ko) * 2003-01-08 2004-07-14 김원호 다이어트 식품용 조제
JP2005082523A (ja) * 2003-09-08 2005-03-31 Toru Hasegawa 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
EP1782807B1 (en) * 2004-08-18 2017-08-09 Mochida Pharmaceutical Co., Ltd. Jelly composition
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JPWO2006054757A1 (ja) * 2004-11-16 2008-06-05 アステラス製薬株式会社 カスパーゼ阻害剤
KR20080009075A (ko) * 2005-03-10 2008-01-24 씰 파마, 인크. 영양 제제
US20060217385A1 (en) * 2005-03-10 2006-09-28 Edwards John B Nutritional preparations
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
MX2008002701A (es) 2005-08-26 2008-03-18 Nestec Sa Nutricion para pacientes obesos.
JP5113527B2 (ja) * 2005-11-11 2013-01-09 持田製薬株式会社 ゼリー組成物
US8367121B2 (en) * 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
JP5176127B2 (ja) * 2006-01-11 2013-04-03 大正製薬株式会社 視覚機能障害の予防または改善剤
US20090311329A1 (en) * 2006-04-20 2009-12-17 Technion Research And Development Foundation Ltd Casein micelles for nanoencapsulation of hydrophobic compounds
JP5300186B2 (ja) * 2006-08-23 2013-09-25 株式会社明治 血中ホモシステイン濃度の上昇を抑制する妊婦用の乳由来組成物
KR100832675B1 (ko) * 2006-09-22 2008-05-26 한상왕 영양 보조제
CN101631542B (zh) 2006-12-28 2011-12-21 三得利控股株式会社 神经再生剂
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
WO2008153220A1 (ja) * 2007-06-13 2008-12-18 Suntory Holdings Limited 血管疾患の予防又は治療剤
ES2445401T3 (es) * 2007-06-26 2014-03-03 N.V. Nutricia Aumentar la memoria en sujetos con mini examen del estado mental de 24-26
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
EP2221059B1 (en) * 2007-10-25 2018-01-17 Nutri Co., Ltd. Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN103705486A (zh) * 2008-01-10 2014-04-09 武田药品工业株式会社 胶囊制剂
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US8865733B2 (en) * 2008-11-06 2014-10-21 Altman Enterprises, LLC Medication and treatment for disease
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
HUE034941T2 (en) 2009-04-29 2018-03-28 Amarin Pharmaceuticals Ie Ltd A stable pharmaceutical formulation and methods for its use
KR101958515B1 (ko) 2009-06-15 2019-03-14 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
EP2480248B1 (en) 2009-09-23 2015-09-02 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CA2825428C (en) 2010-02-12 2022-06-14 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9216209B1 (en) 2011-06-06 2015-12-22 Kilmer S. McCully Compositions and method for utilization of thioretinamide in therapy of degenerative diseases of aging
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013235266B2 (en) 2012-03-20 2017-10-19 Particle Dynamics International, Llc Gelling agent-based dosage form
CA3067008C (en) 2012-06-29 2021-10-26 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CN103432156A (zh) * 2013-08-30 2013-12-11 深圳奥萨医药有限公司 ω-3脂肪酸和B族维生素的药物组合物及其用途
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
WO2015142500A2 (en) 2014-03-21 2015-09-24 Bodybio Inc. Compositions and methods for treating addiction
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10730821B2 (en) * 2015-11-23 2020-08-04 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11110113B2 (en) 2016-11-03 2021-09-07 Gentelon, Inc. Compositions and methods for treating depression
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
HUE067138T2 (hu) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ireland Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
GB9715203D0 (en) * 1997-07-19 1997-09-24 Piper Edwina M Composition

Also Published As

Publication number Publication date
EP1200085A1 (en) 2002-05-02
KR20020025088A (ko) 2002-04-03
MXPA01013210A (es) 2004-06-03
HUP0202342A2 (hu) 2002-11-28
TR200200045T2 (tr) 2002-05-21
RU2001134300A (ru) 2003-08-27
GB9916536D0 (en) 1999-09-15
CZ200258A3 (cs) 2002-06-12
EE200200021A (et) 2003-04-15
SK332002A3 (en) 2002-12-03
NO20020090D0 (no) 2002-01-08
NZ516101A (en) 2003-06-30
PL352185A1 (en) 2003-08-11
HUP0202342A3 (en) 2003-02-28
IL147556A0 (en) 2002-08-14
JP2003504333A (ja) 2003-02-04
CN1223346C (zh) 2005-10-19
CA2377502A1 (en) 2001-01-18
WO2001003696A1 (en) 2001-01-18
BR0013157A (pt) 2002-04-02
US20050147665A1 (en) 2005-07-07
AU6167800A (en) 2001-01-30
CN1361690A (zh) 2002-07-31
IS6205A (is) 2001-12-18
HK1042853A1 (zh) 2002-08-30
ZA200200259B (en) 2002-12-24

Similar Documents

Publication Publication Date Title
NO20020090D0 (no) Farmasöytiske og n¶ringsformuleringer inneholdende essensielle fettsyrer og homocystein-senkende midler
NO973283D0 (no) Konjugater mellom terapeutiske forbindelser og fettsyrer
ID24654A (id) Formulasi farmasi omeprazola
ID23299A (id) Formulasi-formulasi farmasi
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
FI950910A (fi) Rasvahappojohdannaiset
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
HUP0201444A3 (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
DK1183026T3 (da) Forbedrede farmaceutiske formuleringer omfattende ritonavir
IS2841B (is) Samstæða hluta og lyfjasamsetningar
NO20004399L (no) Koleinsyreamider og farmasøytiske sammensetninger
DE60018967D1 (de) Inierzierbare valnemulin formulierung
HUP0303694A3 (en) Aza-amino acid derivatives and pharmaceutical
ITMI941169A0 (it) Formulazioni farmaceutiche
AR025867A1 (es) Formulacion portasdora farmaceutica
HUP0500956A3 (en) Oxapenem-3-carboxylic acids and pharmaceutical compositions containing them
IL144706A0 (en) Ether type lipid a-1 carboxylic acid analogue and pharmaceutical compositions containing the same
HUP0102705A3 (en) Alpha-amino acid phenyl ester derivatives and their use and pharmaceutical compositions comprising them
NO306491B1 (no) Oppdrettsmaer og anvendelse derav
SE9803619D0 (sv) Fatty acid formulation
IT1313134B1 (it) Dispositivo gonfiabile per l'esposizione di messaggi pubblicitari
SE9904414D0 (sv) Pharmaceutical composition and use